VistaGen Therapeutics (NASDAQ:VTGN) Stock Price Passes Below 50 Day Moving Average – Should You Sell?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.25 and traded as low as $0.24. VistaGen Therapeutics shares last traded at $0.2434, with a volume of 319,344 shares.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Trading Up 0.2%

The stock has a market cap of $10.80 million, a P/E ratio of -0.15 and a beta of 0.39. The stock’s fifty day moving average price is $0.25 and its 200 day moving average price is $0.48.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%.The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. As a group, sell-side analysts forecast that VistaGen Therapeutics, Inc. will post -1.45 earnings per share for the current year.

Institutional Trading of VistaGen Therapeutics

Several institutional investors have recently bought and sold shares of the company. ADAR1 Capital Management LLC bought a new stake in VistaGen Therapeutics during the 2nd quarter valued at about $79,000. BlackRock Inc. bought a new position in shares of VistaGen Therapeutics in the second quarter worth approximately $78,000. Renaissance Technologies LLC grew its holdings in shares of VistaGen Therapeutics by 81.2% during the first quarter. Renaissance Technologies LLC now owns 291,300 shares of the company’s stock valued at $166,000 after buying an additional 130,509 shares during the last quarter. AdvisorShares Investments LLC grew its holdings in shares of VistaGen Therapeutics by 10.8% during the first quarter. AdvisorShares Investments LLC now owns 277,110 shares of the company’s stock valued at $158,000 after buying an additional 26,922 shares during the last quarter. Finally, Seven Fleet Capital Management LP bought a new stake in shares of VistaGen Therapeutics during the fourth quarter valued at approximately $42,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.